Cart
sales@molnova.com
SB-215505
CAS No. 162100-15-4
SB-215505( —— )
Catalog No. M34411 CAS No. 162100-15-4
SB-215505 is a subtype-selective 5-HT2B receptor antagonist that inhibits 5-HT2B, 5-HT2A, and 5-HT2C.SB-215505 can be used to study prostate cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 345 | In Stock |
|
| 10MG | 472 | In Stock |
|
| 25MG | 775 | In Stock |
|
| 50MG | 1051 | In Stock |
|
| 100MG | 1423 | In Stock |
|
| 200MG | 1841 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSB-215505
-
NoteResearch use only, not for human use.
-
Brief DescriptionSB-215505 is a subtype-selective 5-HT2B receptor antagonist that inhibits 5-HT2B, 5-HT2A, and 5-HT2C.SB-215505 can be used to study prostate cancer.
-
DescriptionSB-215505 is a potent and subtype-selective 5-HT2B receptor antagonist with pKi values of 8.3, 6.77, 7.66 for 5-HT2B, 5-HT2A, 5-HT2C, respectively. SB-215505 increases wakefulness and motor activity in rats.
-
In VitroSB-215505 is 30 fold selective for the 5-HT2B over the 5-HT2A receptor, and only marginally selective over the 5-HT2C receptor.
-
In VivoSB-215505 (0.1-1.0 mg/kg; i.p.; two doses) dose-dependently increases wakefulness (W) and decreases IS, PS, SWS-2.Animal Model:Male Sprague-Dawley rats weighing 230-260 g Dosage:0.1, 0.3 and 1.0 mg/kg Administration:IP; two doses (4 days between two doses) Result:Dose-dependently increased wakefulness (W) and decreased intermediate stage of sleep (IS), paradoxical sleep (PS), SWS-2.
-
Synonyms——
-
PathwayGPCR/G Protein
-
Target5-HT Receptor
-
Recptor5-HT Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number162100-15-4
-
Formula Weight337.8
-
Molecular FormulaC19H16ClN3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCc1cc2CCN(C(=O)Nc3cccc4ncccc34)c2cc1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. C Reavill, et al. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4.?
molnova catalog
related products
-
Ziprasidone
A full antagonist of D2 and 5-HT2A receptors with Ki of 6.8 and 0.6 nM, respectively; also is a partial agonist of 5-HT1A, and a partial antagonist of 5-HT2C and 5-HT1D receptors.
-
PF-05212377
PF-05212377 (SAM-760, PF 5212377) is a potent and selective 5-HT6 receptor antagonist with potential therapy for the symptomatic treatment of mild to moderate Alzheimer's disease.
-
Sarizotan 2HCl
Sarizotan 2HCl is an hERG channel inhibitor and 5-hydroxytryptamine 5-HT1A receptor agonist with potential antidepressant effects for the study of Parkinsonian movement disorders.
